AbCellera Biologics Balance Sheet Health
Financial Health criteria checks 6/6
AbCellera Biologics has a total shareholder equity of $1.1B and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $1.5B and $333.2M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$698.02m |
| Equity | US$1.13b |
| Total liabilities | US$333.18m |
| Total assets | US$1.46b |
Recent financial health updates
Recent updates
Companies Like AbCellera Biologics (NASDAQ:ABCL) Are In A Position To Invest In Growth
May 29
AbCellera: Cash Providing Shelter From Market Weakness
May 16AbCellera: Victim Of Its Own Success
Feb 28AbCellera Biologics: Continuing To Expand Partnerships
Feb 13Is Now The Time To Put AbCellera Biologics (NASDAQ:ABCL) On Your Watchlist?
Feb 04AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Could Be 31% Below Their Intrinsic Value Estimate
Nov 29AbCellera Biologics: Many Reasons To Own This Undervalued Stock
Sep 06AbCellera Biologics: COVID Antibody Set To Provide Continued Funding
Aug 14AbCellera partnering with Atlas Ventures on development of therapeutic antibodies
Aug 03AbCellera Biologics: Fully Funded, With New Opportunities And Massive Insider Buying
Jun 06Need To Know: Analysts Are Much More Bullish On AbCellera Biologics Inc. (NASDAQ:ABCL)
May 13Not Many Are Piling Into AbCellera Biologics Inc. (NASDAQ:ABCL) Stock Yet As It Plummets 25%
May 07AbCellera Biologics: Potentially Bottoming Out Amidst Terrible Market Sentiment
Apr 22AbCellera Biologics: Bebtelovimab Supply Deal Provides A Much Needed Shot In The Arm
Feb 11AbCellera Biologics: Potentially Worth Over $41 Currently, Without COVID Revenues
Dec 05AbCellera Biologics: The COVID Premium Is Gone, Thanks To Merck - Time To Buy
Oct 18AbCellera Biologics: I Was Wrong
Aug 20AbCellera Biologics Inc. (NASDAQ:ABCL) Analysts Are More Bearish Than They Used To Be
Aug 17AbCellera Biologics: A Buy At Current Prices
Aug 06Financial Position Analysis
Short Term Liabilities: ABCL's short term assets ($813.9M) exceed its short term liabilities ($104.9M).
Long Term Liabilities: ABCL's short term assets ($813.9M) exceed its long term liabilities ($228.3M).
Debt to Equity History and Analysis
Debt Level: ABCL is debt free.
Reducing Debt: ABCL has no debt compared to 5 years ago when its debt to equity ratio was 38.1%.
Debt Coverage: ABCL has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: ABCL has no debt, therefore coverage of interest payments is not a concern.